{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:04:45Z","timestamp":1785683085416,"version":"3.56.0"},"reference-count":76,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":3202,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p>Serious drug\u2010drug interactions have contributed to recent U.S. market withdrawals and also recent nonapprovals of a few new molecular entities. Many of these interactions involved the inhibition or induction of metabolizing enzymes and efflux transporters, resulting in altered systemic exposure and adverse drug reactions or loss of efficacy. In addition to drug\u2010drug interactions, drug\u2014dietary supplement and drug\u2014citrus fruit interactions, among others, could also cause adverse drug reactions or loss of efficacy and are important issues to consider in the evaluation of new drug candidates. This commentary reviews (1) the current understanding of the mechanistic basis of these interactions, (2) issues to consider in the interpretation of study results, and (3) recent labeling examples to illustrate the translation of study results to information useful for patients and health care providers.<\/jats:p>","DOI":"10.1177\/0091270004265367","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T20:23:25Z","timestamp":1084566205000},"page":"559-569","source":"Crossref","is-referenced-by-count":113,"title":["Drug\u2010Drug, Drug\u2014Dietary Supplement, and Drug\u2014Citrus Fruit and Other Food Interactions: What Have We Learned?"],"prefix":"10.1002","volume":"44","author":[{"given":"Shiew\u2010Mei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Lesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.337"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2505"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2000.6.415"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922011764"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008515"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109366"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.12.1311"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.3.1042"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.1"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00171-0"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342010-00003"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121152"},{"key":"e_1_2_7_14_2","volume-title":"Guidance for Industry: Drug Metabolism\/Drug Interactions in the Drug Development Process: Studies","author":"Food and Drug Administration","year":"1997"},{"key":"e_1_2_7_15_2","volume-title":"Guidance for Industry: In Vivo Metabolism\/Drug Interactions: Study Design, Data Analysis and Recommendation for Dosing and Labeling","author":"Food and Drug Administration","year":"1999"},{"key":"e_1_2_7_16_2","unstructured":"Food and Drug Administration:Issues and challenges in the evaluation and labeling of drug interaction potentials of NME. Paper presented at the Food and Drug Administration Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology Subcommittee meeting Rockville MD April 23 2003. Retrieved fromhttp:www.fda.govohrmsdocketsac03slides3947s2.htm;http:www.fda.govohrmsdocketsac03transcripts3947T2.htm."},{"key":"e_1_2_7_17_2","unstructured":"Food and Drug Administration:CYP2C8and CYP2B6\u2010 based drug interaction. Paper presented at the Food and Drug Administration Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology Subcommittee meeting Rockville MD November 18 2003. Retrieved fromhttp:www.fda.govohrmsdockets."},{"issue":"247","key":"e_1_2_7_18_2","first-page":"81082","article-title":"Labeling guideline","volume":"65","year":"2000","journal-title":"Fed Reg"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.116891"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.7.815"},{"key":"e_1_2_7_21_2","volume-title":"Guidance for Industry: Exposure\u2010Response Relationship, Study Design, Data Analysis, and Regulatory Applications","author":"Food and Drug Administration","year":"2003"},{"key":"e_1_2_7_22_2","unstructured":"BlasettoJ:Crestor\u00ae clinical development efficacy. Paper presented at the Endocrine and Metabolic Drugs Advisory Committee meeting Gaithersburg MD July 9 2003. Retrieved from cdernet.http:cder.fda.govACSindex.html."},{"key":"e_1_2_7_23_2","unstructured":"LubasL:Crestor\u00ae safety and dosing. Paper presented at the Endocrine and Metabolic Drugs Advisory Committee meeting Gaithersburg MD July 9 2003. Retrieved from cdernet.http:cder.fda.govACSindex.html."},{"key":"e_1_2_7_24_2","unstructured":"Crestor\u00ae approved labeling. Retrieved fromhttp:www.fda.govcderapprovalindex.htm."},{"key":"e_1_2_7_25_2","unstructured":"Levitra\u00ae approved labeling. Retrieved fromhttp:www.fda.govcderapprovalindex.htm."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.402"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.130155097"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05712-8"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05467-7"},{"key":"e_1_2_7_30_2","unstructured":"FDA public health advisory:risk of drug interactions with St John's wort and indinavir and other drugs. Retrieved fromhttp:www.fda.govcderdrugadvisorystjwort.htm."},{"key":"e_1_2_7_31_2","unstructured":"ChenMC HuangS\u2010M MozerskyR BeitzJ HonigP:Drug interactions involving St. John's wort: data from FDA's adverse reaction reporting system. Paper presented at the annual meeting of the American Association of Pharmaceutical Scientists Denver CO October 2001."},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(01)00127-8"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.124080"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.08.009"},{"key":"e_1_2_7_35_2","unstructured":"A catalog of FDA approved drug products. Retrieved fromhttp:www.fda.govcderapprovalindex.htm;http:pdrel.thomsonhc.compdrellibrarian."},{"key":"e_1_2_7_36_2","unstructured":"FTC warning. Retrieved fromhttp:www.ftc.govopa200106cureall.htm."},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0944-7113(00)80044-6"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)90703-X"},{"key":"e_1_2_7_39_2","doi-asserted-by":"crossref","unstructured":"YinOQ Tomlinson B ChowMS:Prediction and mechanism of herb\u2010drug interaction: effect of gingko biloba on omega zole in Chinese subjects. Paper presented at the annual meeting of the American Society of Clinical Pharmacology Washington DC April 2003. Abstract inClin Pharmacol Ther2003;P94.","DOI":"10.1016\/S0009-9236(03)90701-6"},{"key":"e_1_2_7_40_2","unstructured":"ChowMS:A pharmacokinetic\u2010pharmacogenamic approach in studying herb\u2010drug interaction. Paper presented at the annual meeting of the American College Clinical Pharmacology Tampa FL September 22 2003."},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.100453001"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90700-9"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110216"},{"issue":"3","key":"e_1_2_7_44_2","first-page":"126","article-title":"Grapefruit juice increases oral nimodipine bioavailability","volume":"36","author":"Fuhr U","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000156"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.t01-1-00687.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050263"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050296"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90068-3"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90056-X"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90034-0"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70133-5"},{"key":"e_1_2_7_53_2","article-title":"Drug interactions with herbal products & grapefruit juice: a conference report","author":"Huang S\u2010M","journal-title":"Clin Pharmacol Ther;"},{"key":"e_1_2_7_54_2","unstructured":"PiazzaT HuangS\u2010M HeppP:FDA evaluation of drug grapefruit interaction labeling. Paper presented at the annual meeting of the American College of Clinical Pharmacology San Francisco September 2002 and at the FDA science forum Washington DC April 2003."},{"key":"e_1_2_7_55_2","unstructured":"WeiX ParkM AhnH:Analysis of grapefruit juice interactions with HMG Coa reducfase inhilators. Paper presented at the American Association of Pharmaceutical Scientists Fourth Annual Meeting and Exposition New Orleans LA November 14 1999."},{"key":"e_1_2_7_56_2","unstructured":"ParkMH MarinsR WeixR GreenM:Rhabdomyolysis associated with lovastatin and grapefruit juice interaction. Paper presented at the FDA Science Forum Washington DC February 2000."},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113185"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002762491370"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003253399"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002239711"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700222011391"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7302.1571"},{"key":"e_1_2_7_63_2","unstructured":"British Committee on Safety of Medicines:Current problems in pharmacovigilance September 2003. Retrieved fromhttp:www.mca.gov.ukourworkmonitorsafequalmedcurrentproblemscpsept2003.pdf."},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7429.1454"},{"key":"e_1_2_7_65_2","unstructured":"Makris M MacleanRM:Interaction between warfarin and cranberry juice. Premature conclusion? Rapid response to Suvarna et al [ref 63]. Retrieved fromhttp:bmj.com."},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90146-1"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050082"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.106464"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00053.x"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530010049034"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00118-8"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1078\/1433-187X-00210"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90185-5"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.23.3036"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1652"},{"key":"e_1_2_7_76_2","volume-title":"Concept Paper: Premarketing Risk Assessment","author":"Food and Drug Administration","year":"2003"},{"key":"e_1_2_7_77_2","unstructured":"Roche letter. Retrieved fromhttp:www.fda.govmedwatchsafety1998posico2.htm."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270004265367","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270004265367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:51:35Z","timestamp":1697525495000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270004265367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1177\/0091270004265367"],"URL":"https:\/\/doi.org\/10.1177\/0091270004265367","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}